Compare Gilead Sciences, Inc. (GILD) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wix.Com Ltd — how do they compare? Gilead Sciences, Inc. trades at $135.89 (market cap $168.35B), while Wix.Com Ltd trades at $67.1 (market cap $2.79B). The key difference: Gilead Sciences, Inc. is far larger — about 60.3× Wix.Com Ltd's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| GILD | WIX | |
|---|---|---|
Market Cap | $168.35B | $2.79B |
Sector | Health | Technology |
52-Week High | $155.80 | $184.24 |
52-Week Low | $110.56 | $40.43 |
Enterprise Value | $191.42B | $3.87B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
WIX trades at $66.60, up 6.69% today, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75. Revenue grew to $1.99B in 2025, though net income margin remains negative at -8.19%. Recent news includes the launch of Symphony by Wix, an AI system for SMBs, but the stock faces multiple class-action lawsuits following a 27% drop after Q1 2026 earnings missed expectations.
The outlook is mixed: strong revenue growth and analyst buy ratings suggest upside, but legal risks and volatile earnings pose significant challenges. Investors should weigh the high P/E of 62.84 against competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
